Cantor Fitzgerald restated their overweight rating on shares of Flexion Therapeutics Inc (NASDAQ:FLXN) in a report released on Saturday. They currently have a $34.00 price target on the specialty pharmaceutical company’s stock.
FLXN has been the topic of several other research reports. BMO Capital Markets reissued an outperform rating and issued a $33.00 price objective on shares of Flexion Therapeutics in a research note on Thursday, December 15th. Janney Montgomery Scott reaffirmed a buy rating and set a $30.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 11th. Raymond James Financial, Inc. began coverage on Flexion Therapeutics in a research report on Thursday, December 22nd. They set a strong-buy rating and a $35.00 target price on the stock. Zacks Investment Research cut Flexion Therapeutics from a buy rating to a hold rating in a research report on Friday, January 13th. Finally, Royal Bank of Canada reaffirmed an outperform rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 11th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $28.68.
Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 3.89% during mid-day trading on Friday, hitting $27.27. The company had a trading volume of 1,532,722 shares. Flexion Therapeutics has a 1-year low of $8.15 and a 1-year high of $28.20. The company’s market capitalization is $865.30 million. The company has a 50-day moving average price of $20.23 and a 200-day moving average price of $19.15.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by $0.08. On average, equities analysts anticipate that Flexion Therapeutics will post ($3.46) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Web Breaking News and is the property of of Web Breaking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at http://www.webbreakingnews.com/2017/03/25/flexion-therapeutics-inc-flxn-receives-overweight-rating-from-cantor-fitzgerald.html.
In other Flexion Therapeutics news, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total transaction of $69,000.00. Following the sale, the chief financial officer now owns 10,777 shares of the company’s stock, valued at approximately $247,871. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Neil Bodick sold 5,000 shares of the stock in a transaction on Friday, January 20th. The shares were sold at an average price of $18.35, for a total value of $91,750.00. Following the sale, the insider now directly owns 60,937 shares in the company, valued at approximately $1,118,193.95. The disclosure for this sale can be found here. Insiders have sold a total of 18,000 shares of company stock worth $358,550 in the last ninety days. Insiders own 18.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in FLXN. Keybank National Association OH boosted its stake in shares of Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 67 shares during the period. SECOR Capital Advisors LP acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $214,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $271,000. Jennison Associates LLC acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $402,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $620,000. 62.25% of the stock is currently owned by institutional investors and hedge funds.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.